Meeting
2018 ASCO Annual Meeting
Quality of life(QoL) outcomes including neuropathy associated scale (FACT-T) from a phase II, multicenter, randomized trial of eribulin plus gemcitabine(EG) versus paclitaxel plus gemcitabine(PG) as first-line chemotherapy for human epidermal growth factor receptor 2 (HER2)- negative metastatic breast cancer(MBC): Korean Cancer Study Group trial (KCSG BR13-11).
Authors
Ji-Yeon Kim
Samsung Medical Center, Seoul, Republic of Korea
Ji-Yeon Kim , Seri Park , Seock-Ah Im , Sung-Bae Kim , Joohyuk Sohn , Keun-Seok Lee , Ki Hyeong Lee , Jee Hyun Kim , Young-Hyuck Im , Tae Yong Kim , Kyung-Hun Lee , Jin-Hee Ahn , Gun Min Kim , In Hae Park , Yee Soo Chae , Soo Jung Lee , Hye Sook Han , Se Hyun Kim , Kyung Hae Jung , Yeon Hee Park
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Patient and Survivor Care
Track
Patient and Survivor Care
Sub Track
Palliative Care and Symptom Management
Clinical Trial Registration Number
NCT02263495
Citation
J Clin Oncol 36, 2018 (suppl; abstr 10117)
DOI
10.1200/JCO.2018.36.15_suppl.10117
Abstract #
10117
Poster Bd #
105
Abstract Disclosures
Similar Posters
Poster
2017 ASCO Annual Meeting
A phase II, multicenter, randomized trial of eribulin plus gemcitabine (EG) vs. paclitaxel plus gemcitabine (PG) in patients with HER2-negative metastatic breast cancer (MBC) as first-line chemotherapy (KCSG BR13-11, NCT02263495).
First Author: Kyung Hae Jung
Poster
2023 ASCO Annual Meeting
Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM).
First Author: Alicia Frances Clare Okines
Poster
2023 ASCO Annual Meeting
Distribution and outcomes of HER2-low and HER2-zero metastatic breast cancer in Black and younger women.
First Author: Paola Zagami
First Author: Cristina I. Truica